New x-ray activated drug injection tested for Hard-to-Treat cancers
NCT ID NCT04389281
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-stage trial is testing a treatment called X-PACT for people with advanced head and neck cancer, breast cancer, soft tissue sarcoma, or melanoma that has not responded to standard treatments. X-PACT involves injecting a drug called methoxsalen directly into the tumor and then activating it with a targeted X-ray beam. The main goal is to check if the treatment is safe, with up to 52 participants receiving multiple injections over several weeks.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
X-PACT (methoxsalen injection plus X-ray activation)
What this could lead to
If it works, this could point toward a new local treatment option for advanced solid tumors that have not responded to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 52 participants, focused on safety. It may not show meaningful tumor shrinkage, and there are risks from the injection and X-ray exposure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Duke University
RECRUITINGDurham, North Carolina, 27710, United States
Contact
Contact
-
Levine Cancer Institute
RECRUITINGCharlotte, North Carolina, 28204, United States
Contact
Contact
-
Prisma Health
RECRUITINGGreenville, South Carolina, 29605, United States
Contact
-
Sibley Hospital - Johns Hopkins University
RECRUITINGWashington D.C., District of Columbia, 20016, United States
Contact